Journal of Hematology & Oncology (2020-11-01)

Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions

  • Li Zhang,
  • Lin Tian,
  • Xiaoyang Dai,
  • Hua Yu,
  • Jiajia Wang,
  • Anhua Lei,
  • Mengmeng Zhu,
  • Jianpo Xu,
  • Wei Zhao,
  • Yuqing Zhu,
  • Zhen Sun,
  • Hao Zhang,
  • Yongxian Hu,
  • Yanlin Wang,
  • Yuming Xu,
  • George M. Church,
  • He Huang,
  • Qinjie Weng,
  • Jin Zhang

Journal volume & issue
Vol. 13, no. 1
pp. 1 – 5


Read online

Abstract The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic. However, there are still major challenges for its wider applications in a variety of cancer types including lack of effectiveness due to the highly complex tumor microenvironment, and the forbiddingly high cost due to the personalized manufacturing procedures. In order to overcome these hurdles, numerous efforts have been spent focusing on optimizing Chimera antigen receptors, engineering and improving T cell capacity, exploiting features of subsets of T cell or NK cells, or making off-the-shelf universal cells. Here, we developed induced pluripotent stem cells (iPSCs)-derived, CAR-expressing macrophage cells (CAR-iMac). CAR expression confers antigen-dependent macrophage functions such as expression and secretion of cytokines, polarization toward the pro-inflammatory/anti-tumor state, enhanced phagocytosis of tumor cells, and in vivo anticancer cell activity. This technology platform for the first time provides an unlimited source of iPSC-derived engineered CAR-macrophage cells which could be utilized to eliminate cancer cells.